Published in Eur J Immunol on June 05, 2014
β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer. Front Pharmacol (2015) 0.82
Integrins Influence the Size and Dynamics of Signaling Microclusters in a Pyk2-dependent Manner. J Biol Chem (2015) 0.75
VARIATIONS IN AFFINITIES OF ANTIBODIES DURING THE IMMUNE RESPONSE. Biochemistry (1964) 11.48
Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68
The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem (2002) 4.11
Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A (2006) 3.54
Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol (2012) 3.43
Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood (1997) 3.19
Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A (2011) 2.65
High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Mol Immunol (2005) 2.54
Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res (2005) 2.39
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs (2010) 2.09
Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res (2000) 2.00
The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem (2005) 1.85
In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol (2000) 1.84
Integrin-dependent organization and bidirectional vesicular traffic at cytotoxic immune synapses. Immunity (2009) 1.74
Cytotoxic T lymphocytes form an antigen-independent ring junction. J Clin Invest (2004) 1.72
Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody. Proc Natl Acad Sci U S A (2012) 1.70
Distinct role of lymphocyte function-associated antigen-1 in mediating effective cytolytic activity by cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (2005) 1.51
N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients. J Proteome Res (2012) 1.46
Structural and functional studies with antibodies to the integrin beta 2 subunit. A model for the I-like domain. J Biol Chem (2000) 1.34
Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR). Cancer Biol Ther (2009) 1.32
IFN-dependent down-regulation of the NKG2D ligand H60 on tumors. J Immunol (2006) 1.31
Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res (2007) 1.27
Protein kinase C theta regulates stability of the peripheral adhesion ring junction and contributes to the sensitivity of target cell lysis by CTL. J Immunol (2008) 1.24
Regulated glycosylation patterns of IgG during alloimmune responses against human platelet antigens. J Proteome Res (2009) 1.24
Alpha-v integrins as therapeutic targets in oncology. Cancer Invest (2007) 1.22
CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer (2004) 1.19
RGD peptides and monoclonal antibodies, antagonists of alpha(v)-integrin, enter the cells by independent endocytic pathways. Lab Invest (2001) 1.17
Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. Br J Cancer (2005) 1.12
CNTO 95, a fully human anti alphav integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells. Clin Exp Metastasis (2007) 1.10
A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer (2011) 1.10
Immunoglobulin G Fc N-glycan profiling in patients with gastric cancer by LC-ESI-MS: relation to tumor progression and survival. Glycoconj J (2011) 1.08
Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin. Mol Cancer Ther (2006) 1.08
Changes in antigen-specific IgG1 Fc N-glycosylation upon influenza and tetanus vaccination. Mol Cell Proteomics (2011) 0.99
Interferon-gamma induction of the human leukocyte antigen-E gene is mediated through binding of a complex containing STAT1alpha to a distinct interferon-gamma-responsive element. J Biol Chem (1996) 0.97
Structural basis for degenerate recognition of natural HIV peptide variants by cytotoxic lymphocytes. J Biol Chem (2006) 0.96
Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity. Blood (2013) 0.93
Fibronectin maintains survival of mouse natural killer (NK) cells via CD11b/Src/beta-catenin pathway. Blood (2009) 0.93
Participation of CD11a-c/CD18, CD2 and RGD-binding receptors in endogenous and interleukin-2-stimulated NK activity of CD3-negative large granular lymphocytes. Int J Cancer (1990) 0.91
Soluble HIV-specific T cell receptor: expression, purification and analysis of the specificity. J Immunol Methods (2003) 0.87
Expression of vitronectin receptor on human NK cells and its role in protein phosphorylation, cytokine production, and cell proliferation. J Immunol (1995) 0.86
A variant human IgG1-Fc mediates improved ADCC. Protein Eng Des Sel (2011) 0.86
Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo. Mol Cancer Ther (2008) 0.85
Tandemly repeated Fc domain augments binding avidities of antibodies for Fcgamma receptors, resulting in enhanced antibody-dependent cellular cytotoxicity. Mol Immunol (2008) 0.82
Expression of cDNAs in human Natural Killer cell lines by retroviral transduction. Methods Mol Biol (2010) 0.81
Enhancement of Natural Killer cell cytotoxicity by a CD18 integrin-activating antibody. Biochem Biophys Res Commun (2007) 0.80
Role of cytogenetics in management of uveal melanoma. Arch Ophthalmol (2008) 2.73
Kinetics of early T cell receptor signaling regulate the pathway of lytic granule delivery to the secretory domain. Immunity (2009) 1.98
Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle (2009) 1.87
Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations. Cancer Prev Res (Phila) (2010) 1.80
Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol (2003) 1.74
Cytotoxic T lymphocytes form an antigen-independent ring junction. J Clin Invest (2004) 1.72
KIR2DL4 is an IL-2-regulated NK cell receptor that exhibits limited expression in humans but triggers strong IFN-gamma production. J Immunol (2003) 1.60
Altered gene expression in phenotypically normal renal cells from carriers of tumor suppressor gene mutations. Cancer Biol Ther (2004) 1.58
Quantum dot/peptide-MHC biosensors reveal strong CD8-dependent cooperation between self and viral antigens that augment the T cell response. Proc Natl Acad Sci U S A (2006) 1.58
ICAM-1 co-stimulates target cells to facilitate antigen presentation. Curr Opin Immunol (2005) 1.55
Enhanced NK-cell development and function in BCAP-deficient mice. Blood (2008) 1.53
Distinct role of lymphocyte function-associated antigen-1 in mediating effective cytolytic activity by cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (2005) 1.51
Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44. J Immunol (2011) 1.37
Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. J Immunol (2008) 1.35
Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR). Cancer Biol Ther (2009) 1.32
NKp44 receptor mediates interaction of the envelope glycoproteins from the West Nile and dengue viruses with NK cells. J Immunol (2009) 1.27
SHP-1- and phosphotyrosine-independent inhibitory signaling by a killer cell Ig-like receptor cytoplasmic domain in human NK cells. J Immunol (2002) 1.26
Cutting edge: KIR2DL4 transduces signals into human NK cells through association with the Fc receptor gamma protein. J Immunol (2005) 1.25
Protein kinase C theta regulates stability of the peripheral adhesion ring junction and contributes to the sensitivity of target cell lysis by CTL. J Immunol (2008) 1.24
Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity. J Clin Invest (2012) 1.22
Parallel purification of three catalytic subunits of the protein serine/threonine phosphatase 2A family (PP2A(C), PP4(C), and PP6(C)) and analysis of the interaction of PP2A(C) with alpha4 protein. Protein Expr Purif (2003) 1.13
Characterization of the recognition of tumor cells by the natural cytotoxicity receptor, NKp44. Biochemistry (2007) 1.12
B-cell adaptor for PI3K (BCAP) negatively regulates Toll-like receptor signaling through activation of PI3K. Proc Natl Acad Sci U S A (2011) 1.12
Distinct molecular mechanisms account for the specificity of two different T-cell receptors. Biochemistry (2003) 1.12
Protein kinase C regulates expression and function of inhibitory killer cell Ig-like receptors in NK cells. J Immunol (2007) 1.10
KIR2DL4 differentially signals downstream functions in human NK cells through distinct structural modules. J Immunol (2008) 1.09
PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. Cancer Immunol Res (2013) 1.06
Immunotherapy of cancer. Eur J Pharmacol (2009) 1.05
TIPE2 protein serves as a negative regulator of phagocytosis and oxidative burst during infection. Proc Natl Acad Sci U S A (2012) 1.04
Targeting αV-integrins decreased metastasis and increased survival in a nude rat breast cancer brain metastasis model. J Neurooncol (2012) 1.03
Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models. Neuro Oncol (2010) 1.02
Tpl2 and ERK transduce antiproliferative T cell receptor signals and inhibit transformation of chronically stimulated T cells. Proc Natl Acad Sci U S A (2008) 0.99
Conjunctival melanoma: bladder and upper urinary tract metastases. J Clin Oncol (2010) 0.99
Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res (2014) 0.99
Ubiquitylation of an internalized killer cell Ig-like receptor by Triad3A disrupts sustained NF-κB signaling. J Immunol (2011) 0.98
Src homology region 2-containing protein tyrosine phosphatase-2 (SHP-2) can play a direct role in the inhibitory function of killer cell Ig-like receptors in human NK cells. J Immunol (2003) 0.97
Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience. AJR Am J Roentgenol (2011) 0.97
How a T cell receptor-like antibody recognizes major histocompatibility complex-bound peptide. J Biol Chem (2008) 0.96
Structural basis for degenerate recognition of natural HIV peptide variants by cytotoxic lymphocytes. J Biol Chem (2006) 0.96
KIR2DL5 can inhibit human NK cell activation via recruitment of Src homology region 2-containing protein tyrosine phosphatase-2 (SHP-2). J Immunol (2004) 0.96
Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther (2006) 0.95
Antibody specific for the peptide.major histocompatibility complex. Is it T cell receptor-like? J Biol Chem (2004) 0.94
Prostaglandin D2 suppresses human NK cell function via signaling through D prostanoid receptor. J Immunol (2007) 0.93
Human and non-human primate intestinal FcRn expression and immunoglobulin G transcytosis. Pharm Res (2013) 0.92
Uveal melanoma trapped in the temple of doom. Am J Ophthalmol (2012) 0.92
Interleukin 6 mediates production of interleukin 10 in metastatic melanoma. Cancer Immunol Immunother (2011) 0.91
Anti-alphav integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats. Cancer Res (2010) 0.91
Side-branch embolization before 90Y radioembolization: rate of recanalization and new collateral development. AJR Am J Roentgenol (2011) 0.90
Major histocompatibility complex class I-intercellular adhesion molecule-1 association on the surface of target cells: implications for antigen presentation to cytotoxic T lymphocytes. Immunology (2004) 0.90
Early arterial stasis during resin-based yttrium-90 radioembolization: incidence and preliminary outcomes. HPB (Oxford) (2013) 0.90
Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res (2005) 0.90
Can oligomeric T-cell receptor be used as a tool to detect viral peptide epitopes on infected cells? Clin Immunol (2008) 0.89
A pilot study of sunitinib malate in patients with metastatic uveal melanoma. Melanoma Res (2012) 0.89
Mechanisms controlling granule-mediated cytolytic activity of cytotoxic T lymphocytes. Immunol Res (2011) 0.89
TCR rearrangement in lymphocytes infiltrating melanoma metastases after administration of autologous dinitrophenyl-modified vaccine. J Immunol (2002) 0.88
High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma. Radiology (2009) 0.88
Evidence that the density of self peptide-MHC ligands regulates T-cell receptor signaling. PLoS One (2012) 0.88
Toxicities after radioembolization with yttrium-90 SIR-spheres: incidence and contributing risk factors at a single center. J Vasc Interv Radiol (2011) 0.87
Soluble HIV-specific T cell receptor: expression, purification and analysis of the specificity. J Immunol Methods (2003) 0.87
Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104. J Leukoc Biol (2005) 0.86
Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth. Pigment Cell Melanoma Res (2014) 0.85
SHP-2 expression negatively regulates NK cell function. J Immunol (2009) 0.85
Antagonism of HIV-specific CD4+ T cells by C-terminal truncation of a minimum epitope. Mol Immunol (2005) 0.84
Enteric alpha defensins in norm and pathology. Ann Clin Microbiol Antimicrob (2012) 0.83
A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. Cancer (2010) 0.83
Moxifloxacin prophylaxis for chemoembolization or embolization in patients with previous biliary interventions: a pilot study. AJR Am J Roentgenol (2011) 0.82
Yttrium-90 Microsphere Brachytherapy for Liver Metastases From Uveal Melanoma: Clinical Outcomes and the Predictive Value of Fluorodeoxyglucose Positron Emission Tomography. Am J Clin Oncol (2016) 0.82
A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment. Melanoma Res (2007) 0.82
Expression of cDNAs in human Natural Killer cell lines by retroviral transduction. Methods Mol Biol (2010) 0.81
Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibody. Int J Gynecol Cancer (2011) 0.81
Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses. Cancer Immunol Immunother (2002) 0.81
Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine. Cancer Immunol Immunother (2011) 0.80
Regulation of natural cytotoxicity receptors by heparan sulfate proteoglycans in -cis: A lesson from NKp44. Eur J Immunol (2015) 0.79
Calculation of survival of patients with stage III melanoma. J Clin Oncol (2005) 0.79
Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: immunoadhesins for human IL-10 with therapeutic potential. Cancer Immunol Immunother (2009) 0.79
A novel mechanism for cancer cells to evade immune attack by NK cells: The interaction between NKp44 and proliferating cell nuclear antigen. Oncoimmunology (2012) 0.79
Measuring intracellular calcium signaling in murine NK cells by flow cytometry. Methods Mol Biol (2010) 0.79
Metastatic signature in lung cancer is associated with sensitivity to anti-integrin α(V) monoclonal antibody intetumumab. Genes Chromosomes Cancer (2014) 0.78
Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma. J Surg Oncol (2011) 0.78
Prohibitins and the cytoplasmic domain of CD86 cooperate to mediate CD86 signaling in B lymphocytes. J Immunol (2012) 0.78
A novel composite immunotoxin that suppresses rabies virus production by the infected cells. J Immunol Methods (2009) 0.78
Differential splicing generates Tvl-1/RFXANK isoforms with different functions. J Biol Chem (2002) 0.77
Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity? Rev Recent Clin Trials (2016) 0.77
Somatostatin receptor scintigraphy in patients with metastatic uveal melanoma. Melanoma Res (2013) 0.77
Introduction of shRNAs into human NK-like cell lines with retrovirus. Methods Mol Biol (2010) 0.77
The potential role of sunitinib targeting melanomas. Expert Opin Investig Drugs (2013) 0.77
Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer. Anticancer Drugs (2013) 0.77
Locoregional treatment of malignant hepatic tumors with biologic response modifiers. Surg Oncol Clin N Am (2008) 0.76
Successes and setbacks of early investigational drugs for melanoma. Expert Opin Investig Drugs (2015) 0.75
Mind the BAP. Pigment Cell Melanoma Res (2011) 0.75
Surgically unresectable regional melanoma metastases in a patient with renal failure and peripheral vascular disease: are there safe and potentially effective treatments? Semin Oncol (2010) 0.75
[Natural killer cells and cancer. Regulation by the killer cell Ig-like receptors (KIR)]. Zhongguo Fei Ai Za Zhi (2010) 0.75
Correction: Cutting Edge: Role of NK Cells and Surfactant Protein D in Dendritic Cell Lymph Node Homing: Effects of Ozone Exposure. J Immunol (2016) 0.75